real-world psa responses to apalutamide or enzalutamide in mcspc
Published 6 months ago • 708 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
15:06
comparing real world evidence to phase iii data on apalutamide for nmcrpc
-
5:53
real-world associations between psa screening and metastatic prostate cancer incidence
-
1:24
real-world psa response data similar to clinical trials in prostate cancer
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
1:01:52
psa test for prostate disease: its clinical use and misuse and how to lower it naturally
-
17:49
long term response to apalutamide and other updates impacting patients with nmcrpc from asco gu ...
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
1:20
panther: apalutamide abiraterone in black and white mcrpc patients
-
1:28
apalutamide plus adt leads to survival benefit in mcspc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
3:43
startar: adt apalutamide rt docetaxel for psa-recurrent prostate cancer following rp
-
1:37
arches: os in mhspc who recieved prior adt and reached low psa further treated with enzalutamide
-
6:42
titan trial
-
1:00
most common side-effect of xtandi
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
3:07
salv-enza: srt enzalutamide in high-risk psa-recurrent prostate cancer after radical prostatectomy
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment